|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CREBZF |
Gene summary for CREBZF |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CREBZF | Gene ID | 58487 |
| Gene name | CREB/ATF bZIP transcription factor | |
| Gene Alias | SMILE | |
| Cytomap | 11q14.1 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9NS37 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 58487 | CREBZF | LZE2T | Human | Esophagus | ESCC | 2.67e-07 | 6.34e-01 | 0.082 |
| 58487 | CREBZF | LZE7T | Human | Esophagus | ESCC | 8.70e-06 | 1.74e-01 | 0.0667 |
| 58487 | CREBZF | LZE8T | Human | Esophagus | ESCC | 2.42e-12 | 2.13e-01 | 0.067 |
| 58487 | CREBZF | LZE20T | Human | Esophagus | ESCC | 1.41e-04 | 2.07e-02 | 0.0662 |
| 58487 | CREBZF | LZE22T | Human | Esophagus | ESCC | 4.67e-03 | 1.36e-01 | 0.068 |
| 58487 | CREBZF | LZE24T | Human | Esophagus | ESCC | 2.57e-17 | 6.26e-01 | 0.0596 |
| 58487 | CREBZF | LZE6T | Human | Esophagus | ESCC | 1.17e-06 | 1.37e-01 | 0.0845 |
| 58487 | CREBZF | P1T-E | Human | Esophagus | ESCC | 3.38e-13 | 3.82e-01 | 0.0875 |
| 58487 | CREBZF | P2T-E | Human | Esophagus | ESCC | 2.32e-21 | 2.46e-01 | 0.1177 |
| 58487 | CREBZF | P4T-E | Human | Esophagus | ESCC | 4.54e-24 | 5.61e-01 | 0.1323 |
| 58487 | CREBZF | P5T-E | Human | Esophagus | ESCC | 2.89e-14 | 1.26e-01 | 0.1327 |
| 58487 | CREBZF | P8T-E | Human | Esophagus | ESCC | 5.10e-16 | 8.84e-02 | 0.0889 |
| 58487 | CREBZF | P9T-E | Human | Esophagus | ESCC | 5.05e-14 | 2.12e-01 | 0.1131 |
| 58487 | CREBZF | P10T-E | Human | Esophagus | ESCC | 4.20e-25 | 3.78e-01 | 0.116 |
| 58487 | CREBZF | P11T-E | Human | Esophagus | ESCC | 8.68e-12 | 4.86e-01 | 0.1426 |
| 58487 | CREBZF | P12T-E | Human | Esophagus | ESCC | 2.47e-18 | 3.22e-01 | 0.1122 |
| 58487 | CREBZF | P15T-E | Human | Esophagus | ESCC | 6.41e-13 | 7.59e-02 | 0.1149 |
| 58487 | CREBZF | P16T-E | Human | Esophagus | ESCC | 3.81e-20 | 3.47e-01 | 0.1153 |
| 58487 | CREBZF | P17T-E | Human | Esophagus | ESCC | 1.49e-11 | 1.86e-01 | 0.1278 |
| 58487 | CREBZF | P20T-E | Human | Esophagus | ESCC | 6.19e-25 | 1.92e-01 | 0.1124 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
| GO:00400295 | Esophagus | ESCC | regulation of gene expression, epigenetic | 74/8552 | 105/18723 | 2.24e-07 | 3.42e-06 | 74 |
| GO:00510908 | Esophagus | ESCC | regulation of DNA-binding transcription factor activity | 252/8552 | 440/18723 | 5.22e-07 | 6.97e-06 | 252 |
| GO:0045814 | Esophagus | ESCC | negative regulation of gene expression, epigenetic | 32/8552 | 50/18723 | 6.90e-03 | 2.52e-02 | 32 |
| GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
| GO:00510902 | Liver | HCC | regulation of DNA-binding transcription factor activity | 220/7958 | 440/18723 | 8.04e-04 | 4.82e-03 | 220 |
| GO:0040029 | Liver | HCC | regulation of gene expression, epigenetic | 61/7958 | 105/18723 | 9.02e-04 | 5.31e-03 | 61 |
| GO:000961515 | Oral cavity | OSCC | response to virus | 215/7305 | 367/18723 | 1.63e-14 | 9.41e-13 | 215 |
| GO:00510907 | Oral cavity | OSCC | regulation of DNA-binding transcription factor activity | 221/7305 | 440/18723 | 9.06e-07 | 1.23e-05 | 221 |
| GO:00400294 | Oral cavity | OSCC | regulation of gene expression, epigenetic | 59/7305 | 105/18723 | 2.62e-04 | 1.68e-03 | 59 |
| GO:000961510 | Prostate | BPH | response to virus | 99/3107 | 367/18723 | 2.82e-07 | 6.07e-06 | 99 |
| GO:00510906 | Prostate | BPH | regulation of DNA-binding transcription factor activity | 100/3107 | 440/18723 | 4.71e-04 | 3.37e-03 | 100 |
| GO:000961514 | Prostate | Tumor | response to virus | 101/3246 | 367/18723 | 6.40e-07 | 1.32e-05 | 101 |
| GO:005109014 | Prostate | Tumor | regulation of DNA-binding transcription factor activity | 105/3246 | 440/18723 | 2.69e-04 | 2.23e-03 | 105 |
| GO:00400291 | Prostate | Tumor | regulation of gene expression, epigenetic | 29/3246 | 105/18723 | 5.72e-03 | 2.66e-02 | 29 |
| GO:000961520 | Thyroid | PTC | response to virus | 162/5968 | 367/18723 | 4.52e-07 | 7.41e-06 | 162 |
| GO:00400297 | Thyroid | PTC | regulation of gene expression, epigenetic | 57/5968 | 105/18723 | 1.60e-06 | 2.25e-05 | 57 |
| GO:005109016 | Thyroid | PTC | regulation of DNA-binding transcription factor activity | 178/5968 | 440/18723 | 7.63e-05 | 6.54e-04 | 178 |
| GO:00458142 | Thyroid | PTC | negative regulation of gene expression, epigenetic | 26/5968 | 50/18723 | 2.44e-03 | 1.27e-02 | 26 |
| GO:0009615111 | Thyroid | ATC | response to virus | 173/6293 | 367/18723 | 4.23e-08 | 7.71e-07 | 173 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| CREBZF | CD8TEFF | Breast | ADJ | PNISR,ARGLU1,LUC7L3, etc. | 1.57e-01 |  |
| CREBZF | CD8TEFF | Breast | IDC | PNISR,ARGLU1,LUC7L3, etc. | 7.95e-02 |  |
| CREBZF | MSC.MVA | Skin | Healthy | METTL2A,AJUBA,TIPARP, etc. | 4.42e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CREBZF | SNV | Missense_Mutation | rs768921956 | c.410N>T | p.Ser137Leu | p.S137L | Q9NS37 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.953) | TCGA-AC-A6IV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CREBZF | insertion | Nonsense_Mutation | novel | c.569_570insTTTAGGCCAAGGTTAGTGA | p.Gly191LeufsTer5 | p.G191Lfs*5 | Q9NS37 | protein_coding | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| CREBZF | insertion | Frame_Shift_Ins | novel | c.698_699insA | p.Ser234GlufsTer70 | p.S234Efs*70 | Q9NS37 | protein_coding | TCGA-E2-A570-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD | ||
| CREBZF | SNV | Missense_Mutation | c.896N>G | p.Ser299Trp | p.S299W | Q9NS37 | protein_coding | deleterious(0) | possibly_damaging(0.59) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
| CREBZF | SNV | Missense_Mutation | c.395N>T | p.Ser132Leu | p.S132L | Q9NS37 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.953) | TCGA-EK-A3GN-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| CREBZF | SNV | Missense_Mutation | rs770349667 | c.65N>A | p.Ser22Asn | p.S22N | Q9NS37 | protein_coding | tolerated_low_confidence(0.18) | benign(0.035) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| CREBZF | SNV | Missense_Mutation | c.331N>A | p.Leu111Met | p.L111M | Q9NS37 | protein_coding | deleterious(0.02) | probably_damaging(0.99) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| CREBZF | SNV | Missense_Mutation | rs777311621 | c.76N>A | p.Ala26Thr | p.A26T | Q9NS37 | protein_coding | deleterious_low_confidence(0.04) | benign(0.007) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CREBZF | SNV | Missense_Mutation | c.883C>T | p.Leu295Phe | p.L295F | Q9NS37 | protein_coding | tolerated(0.11) | probably_damaging(0.997) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CREBZF | SNV | Missense_Mutation | novel | c.958G>A | p.Glu320Lys | p.E320K | Q9NS37 | protein_coding | tolerated(0.06) | benign(0.08) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |